Sera Prognostics (NASDAQ:SERA) Posts Earnings Results, Misses Estimates By $0.02 EPS

Sera Prognostics (NASDAQ:SERA) posted its quarterly earnings results on Wednesday. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02), Zacks reports. The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.01 million. During the same quarter in the previous year, the firm posted ($0.25) EPS.

Sera Prognostics Trading Up 1.5 %

NASDAQ SERA opened at $4.14 on Thursday. The company’s 50-day moving average price is $5.06 and its 200-day moving average price is $6.60. The stock has a market cap of $139.82 million, a PE ratio of -4.18 and a beta of 0.89. Sera Prognostics has a 12 month low of $3.84 and a 12 month high of $12.36.

Insider Transactions at Sera Prognostics

In related news, insider Robert Gardner Harrison sold 14,209 shares of the company’s stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $7.39, for a total value of $105,004.51. Following the completion of the sale, the insider now directly owns 116,837 shares of the company’s stock, valued at $863,425.43. This represents a 10.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Joshua Phillips sold 12,163 shares of the company’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $6.39, for a total transaction of $77,721.57. Following the completion of the sale, the director now directly owns 2 shares of the company’s stock, valued at approximately $12.78. This trade represents a 99.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 69,877 shares of company stock worth $480,677. Insiders own 15.80% of the company’s stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.